Hims & Hers Health (NYSE:HIMS) Given Equal Weight Rating at Morgan Stanley

Morgan Stanley restated their equal weight rating on shares of Hims & Hers Health (NYSE:HIMS) in a research report released on Wednesday,Benzinga reports. They currently have a $40.00 target price on the stock.

A number of other equities analysts have also commented on the stock. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $61.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, June 4th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Bank of America boosted their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research report on Tuesday, April 29th. Piper Sandler reissued a “neutral” rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, Leerink Partners boosted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $38.00.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $57.51 on Wednesday. Hims & Hers Health has a 12 month low of $13.47 and a 12 month high of $72.98. The firm has a market capitalization of $12.87 billion, a P/E ratio of 130.71 and a beta of 2.09. The company’s fifty day moving average price is $43.92 and its two-hundred day moving average price is $37.81.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. During the same quarter in the previous year, the business posted $0.05 EPS. The firm’s revenue was up 110.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $33.98, for a total value of $4,353,755.46. Following the completion of the transaction, the chief executive officer now owns 173,655 shares in the company, valued at approximately $5,900,796.90. This represents a 42.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Irene Becklund sold 2,203 shares of the company’s stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the transaction, the insider now owns 8,007 shares of the company’s stock, valued at approximately $230,441.46. This trade represents a 21.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 628,067 shares of company stock valued at $25,832,688 in the last quarter. Insiders own 13.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Blume Capital Management Inc. grew its position in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health in the 1st quarter worth about $30,000. Smartleaf Asset Management LLC grew its position in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares during the last quarter. Summit Securities Group LLC bought a new position in Hims & Hers Health in the 4th quarter worth about $38,000. Finally, UMB Bank n.a. grew its position in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after purchasing an additional 933 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.